Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kilitch Drugs (India) Limited has submitted copies of the newspaper publication of its Q3 FY26 unaudited financial results (quarter ended 31st December 2025) to BSE and NSE. The results were published in both Marathi and English editions on 13th February 2026, as required under SEBI Listing Regulations. On a consolidated basis, total income from operations stood at Rs. 5,380.80 lakhs, up from Rs. 4,892.45 lakhs in the previous quarter but lower than Rs. 5,616.61 lakhs in Q3 FY25. Net profit after tax was Rs. 431.54 lakhs, a sharp sequential decline from Rs. 804.00 lakhs in Q2 FY26. On a standalone basis, profit after tax came in at Rs. 489.08 lakhs versus Rs. 871.57 lakhs in the preceding quarter.
This is a routine compliance filing confirming that the Q3 results were published in newspapers as mandated. The embedded numbers suggest a sequential dip in consolidated profitability, which investors should track once the detailed results are reviewed. No new strategic announcement — primarily a procedural disclosure.